Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer

Aveo Pharmaceuticals Inc AVEO will present new long-term progression-free survival (PFS) data from the Phase 3 TIVO-3 study in kidney cancer at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.

  • The trial is evaluating Fotivda (tivozanib) to Bayer AG's BAYRY Nexavar (sorafenib) in advanced renal cell carcinoma (RCC) patients following two or more prior systemic therapies.
  • "This marks the first presentation of five-year follow-up data for patients being treated in the third- or fourth-line RCC setting and helps guide clinical treatment," said Michael Bailey, President, and CEO.
  • Landmark five-year follow-up data show PFS rates are consistently higher with Fotivda vs. sorafenib, with 12% vs. 2% and 8% vs. 0% at three and four years, respectively. 
  • Long-term PFS represents a clinically meaningful outcome for patients in the third- and fourth-line treatment setting.
  • Long-term overall survival was also analyzed, and a non-significant trend favoring Fotivda continued to emerge with the accumulation of events (HR, 0.89).
  • Price Action: AVEO shares are up 0.57% at $3.52 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsPhase 3 Trialrenal cell carcinoma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!